Retifanlimab gets knocked back by a US adcom. Could a rival now beat it to become the eighth anti-PD-(L)1 to reach the US market?
Promises to act on pharma’s financial toxicity increasingly seem to lack bite, but EQRX promises to follow its words with real action.
A Vantage analysis suggests which small biotechs might seriously have to rethink R&D spending plans in the wake of Covid-19.
After last year’s flop of Prothena’s NEOD001, Takeda’s Ninlaro fails to treat the underlying cause of the non-genetic form of this disease.
The value of Mustang Bio has tripled on data on its immune deficiency gene therapy. But investors might be too keen – and also too late.
A price war over anti-PD-(L)1 drugs is raging in China, less than a year after the first one was approved. When could the US see something similar?